NL-OMON20622尚未招募不适用
A phase I open-label clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid tumors
VU University Medical Center0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically confirmed advanced, solid malignancy;
- •2. Refractory or not amenable to standard therapy;
排除标准
- •1. Major surgery within 28 days before the initiation of study treatment;
- •2. Any serious non-healing wounds, ulcers, or bone fractures within 28 days prior to the initiation of study treatment;
研究者
相似试验
已完成
不适用
A phase I open-label clinical trial, evaluating the therapeutic vaccine hVEGF26-104/RFASE in patients with advanced solid tumorsadvanced cancerAdvanced solid tumor10027655NL-OMON47883Vrije Universiteit Medisch Centrum27
已完成
1 期
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung CancerAdvanced Lung CancerNCT04672356Innovent Biologics (Suzhou) Co. Ltd.19
已完成
1 期
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLCAdvanced Lung CancerNCT04672369Innovent Biologics (Suzhou) Co. Ltd.42
Unknown
1 期
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 AntibodySolid TumorNCT04866485Harbour BioMed (Guangzhou) Co. Ltd.66
Unknown
1 期
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid TumorsSolid TumorsNCT05149027Harbour BioMed (Guangzhou) Co. Ltd.67